

Basal Ganglia Diseases

[View the current Basal Ganglia Diseases InDepth page on BioPortfolio.com](#) (PDF)

(http://www.bioportfolio.com/indepth/Basal_Ganglia_Diseases.html) - Regularly Updated.

Recent Publications on Basal Ganglia Diseases:



- [\[Basal ganglia and psychiatric disorders: an experimental validation\]](#)
Abnormal movements and behavioral disorders are characteristic... 18th November, 2009
Inserm unite 679, hopital de la Salpetriere, 47, boulevard de l'Hopital,- Ann Pharm Fr. 2009
Sep;67(5):320-34. Epub 2009 Aug 8. ([DOI Direct Link](#))
- [\[An 8-year-old boy presenting with progressive extrapyramidal symptoms during total parenteral nutrition\]](#)
Response inhibition is a component of executive functions, which can be... 10th November, 2009
- No To Hattatsu. 2009 Sep;41(5):325-6.
- [\[SLC25A19 mutation as a cause of neuropathy and bilateral striatal necrosis.\]](#)
Four patients, aged 7-20 years, suffered from recurrent episodes of... 30th October, 2009
Department of Human Genetics and Metabolic Diseases, Hadassah-Hebrew- Ann Neurol. 2009
Sep;66(3):419-24. ([DOI Direct Link](#))
- [\[Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis.\]](#)
BACKGROUND: Psychoactive substances (PAS) may interact with antipsychotics... 30th October, 2009
Centre de recherche Fernand-Seguin, Department of Psychiatry, Faculty of- Schizophr Res. 2009
Sep;113(2-3):181-8. Epub 2009 Jul 15. ([DOI Direct Link](#))
- [\[Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.\]](#)
BACKGROUND: We report the case of a 16-year-old male with... 27th October, 2009
The Children's Hospital- J Intellect Dev Disabil. 2009 Sep;34(3):275-9. ([DOI Direct Link](#))
- [\[Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study.\]](#)
BACKGROUND: Extrapyramidal signs (EPSs) are commonly accepted as a feature... 24th October, 2009
Memory Research Resource Center for Alzheimer's Disease, Neurology- Arch Neurol. 2009
Sep;66(9):1120-6. ([DOI Direct Link](#))
- [\[Clinical features of neuroferritinopathy\]](#)
Neuroferritinopathy is an autosomal dominant basal ganglia disease with... 23rd October, 2009
Department of Neurology, Interdisciplinary Graduate School of Medicine and- Rinsho Shinkeigaku.
2009 May;49(5):254-61.
- [\[Exploring clinical characteristics of bipolar depression: internal structure of the bipolar depression rating scale.\]](#)
OBJECTIVE: Due to its pleomorphic phenomenology, the clinical features of... 22nd October, 2009

Department of Neuropsychiatry, Seoul National University Bundang Hospital, - Aust N Z J Psychiatry. 2009 Sep;43(9):830-7. ([DOI Direct Link](#))

- [Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.](#)
*OBJECTIVE: To investigate the efficacy and safety of quetiapine for...*21st October, 2009
Department of Psychiatry, Uijeongbu St. Mary's Hospital, The Catholic- Hum Psychopharmacol. 2009 Aug;24(6):447-52. ([DOI Direct Link](#))
- [Predicting age-specific dosing of antipsychotics.](#)
*Antipsychotic medications are the standard of care for both acute and...*10th October, 2009
Centre for Addiction and Mental Health, Geriatric Mental Health Program, - Clin Pharmacol Ther. 2009 Oct;86(4):360-2. ([DOI Direct Link](#))
- [\[Lesion in the basal ganglia and brain stem compatible with neuro-Behcet's disease\]](#)
*OBJECTIVE: To investigate the efficacy and safety of quetiapine for...*1st October, 2009
- Rev Neurol. 2009 Jul 16-31;49(2):111-2.
- [Response inhibition subprocesses and dopaminergic pathways: Basal ganglia disease effects.](#)
*Response inhibition is a component of executive functions, which can be...*29th September, 2009
Institute for Cognitive Neuroscience, Biopsychology, Ruhr-University of- Neuropsychologia. 2009 Sep 24. ([DOI Direct Link](#))
- [Updating genetic studies in familial idiopathic basal ganglia calcification.](#)
*OBJECTIVE: Due to its pleomorphic phenomenology, the clinical features of...*24th September, 2009
- South Med J. 2009 Sep;102(9):989. ([DOI Direct Link](#))
- [Tardive dyskinesia in a patient treated with quetiapine.](#)
*Quetiapine is an atypical antipsychotic that is believed to have a low D2...*20th August, 2009
Second Department of Psychiatry, University of Athens, Medical School, - World J Biol Psychiatry. 2009;10(1):54-7.
- [Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseases.](#)
*Mitochondrial dysfunctions have been implicated in the cellular processes...*18th August, 2009
Institut de Biologie du Developpement de Marseille-Luminy (IBDML), UMR6216- Biochim Biophys Acta. 2009 Aug 14. ([DOI Direct Link](#))

Basal Ganglia Diseases Patents:



- 7498361- [Methods of treating tardive dyskinesia and other movement disorders](#)
- 5322682- [Method for quantitatively measuring and mapping stored iron in tissue using MRI](#)
- 5393784- [Treatment of tardive dyskinesia with leucine, isoleucine, valine or mixtures thereof](#)
- 5670539- [Treatment of movement disorders using large neutral amino acids](#)
- 5919823- [Treatment of secondary movement disorders using large neutral amino acids](#)
- 5952389- [Methods of treating tardive dyskinesia and other movement disorders](#)
- 6294583- [Methods of treating tardive dyskinesia and other movement disorders](#)
- 6391922- [Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders](#)
- 6689816- [Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders](#)
- 7087574- [Brain associated inhibitor of tissue-type plasminogen activator](#)

- 7235529- [Brain-associated inhibitor of tissue-type plasminogen activator](#)
- 4874694- [Use of phosphoprotein patterns for diagnosis of neurological and psychiatric disorders](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

